BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33856525)

  • 21. Transport of hypoxia-inducible factor HIF-1alpha into the nucleus involves importins 4 and 7.
    Chachami G; Paraskeva E; Mingot JM; Braliou GG; Görlich D; Simos G
    Biochem Biophys Res Commun; 2009 Dec; 390(2):235-40. PubMed ID: 19788888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
    Benkova K; Mihalyova J; Hajek R; Jelinek T
    Blood Rev; 2021 Mar; 46():100758. PubMed ID: 32972802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents.
    Gerecitano J
    J Hematol Oncol; 2014 Oct; 7():67. PubMed ID: 25281264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin.
    Nair JS; Musi E; Schwartz GK
    Clin Cancer Res; 2017 Aug; 23(15):4301-4311. PubMed ID: 28314790
    [No Abstract]   [Full Text] [Related]  

  • 25. Atypical CRM1-dependent nuclear export signal mediates regulation of hypoxia-inducible factor-1alpha by MAPK.
    Mylonis I; Chachami G; Paraskeva E; Simos G
    J Biol Chem; 2008 Oct; 283(41):27620-27627. PubMed ID: 18687685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Andrographolide reduced VEGFA expression in hepatoma cancer cells by inactivating HIF-1α: The involvement of JNK and MTA1/HDCA.
    Shi L; Zhang G; Zheng Z; Lu B; Ji L
    Chem Biol Interact; 2017 Aug; 273():228-236. PubMed ID: 28651835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
    Ming M; Wu W; Xie B; Sukhanova M; Wang W; Kadri S; Sharma S; Lee J; Shacham S; Landesman Y; Maltsev N; Lu P; Wang YL
    Mol Cancer Ther; 2018 Dec; 17(12):2564-2574. PubMed ID: 30510142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
    Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
    Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
    Azmi AS; Muqbil I; Wu J; Aboukameel A; Senapedis W; Baloglu E; Bollig-Fischer A; Dyson G; Kauffman M; Landesman Y; Shacham S; Philip PA; Mohammad RM
    Sci Rep; 2015 Nov; 5():16077. PubMed ID: 26536918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIF-1α-Mediated Mitophagy Determines ZnO Nanoparticle-Induced Human Osteosarcoma Cell Death both In Vitro and In Vivo.
    He G; Pan X; Liu X; Zhu Y; Ma Y; Du C; Liu X; Mao C
    ACS Appl Mater Interfaces; 2020 Oct; 12(43):48296-48309. PubMed ID: 33054172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
    Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
    Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Saikosaponin-D enhances radiosensitivity of hepatoma cells under hypoxic conditions by inhibiting hypoxia-inducible factor-1α.
    Wang BF; Wang XJ; Kang HF; Bai MH; Guan HT; Wang ZW; Zan Y; Song LQ; Min WL; Lin S; Cheng YA
    Cell Physiol Biochem; 2014; 33(1):37-51. PubMed ID: 24401554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
    Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
    Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
    [No Abstract]   [Full Text] [Related]  

  • 34. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.
    Nakayama R; Zhang YX; Czaplinski JT; Anatone AJ; Sicinska ET; Fletcher JA; Demetri GD; Wagner AJ
    Oncotarget; 2016 Mar; 7(13):16581-92. PubMed ID: 26918731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Curcumin decreases survival of Hep3B liver and MCF-7 breast cancer cells: the role of HIF.
    Ströfer M; Jelkmann W; Depping R
    Strahlenther Onkol; 2011 Jul; 187(7):393-400. PubMed ID: 21713389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
    Sun H; Lin DC; Cao Q; Guo X; Marijon H; Zhao Z; Gery S; Xu L; Yang H; Pang B; Lee VK; Lim HJ; Doan N; Said JW; Chu P; Mayakonda A; Thomas T; Forscher C; Baloglu E; Shacham S; Rajalingam R; Koeffler HP
    Cancer Res; 2016 May; 76(9):2687-97. PubMed ID: 26956669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
    Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
    J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown
    Wahba A; Rath BH; O'Neill JW; Camphausen K; Tofilon PJ
    Mol Cancer Ther; 2018 Aug; 17(8):1717-1726. PubMed ID: 29866745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
    Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
    Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.